financetom
Business
financetom
/
Business
/
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million
Nov 4, 2025 8:57 AM

11:34 AM EST, 11/04/2025 (MT Newswires) -- Royalty Pharma ( RPRX ) said Tuesday it has acquired a royalty interest in Alnylam Pharmaceuticals' ( ALNY ) Amvuttra from Blackstone (BX) Life Sciences-managed funds for $310 million.

Royalty Pharma ( RPRX ) said it acquired Blackstone's 1% royalty on global net sales of Amvuttra, a treatment of a disease caused by misfolded proteins that pile up in the nerves, heart and GI tract.

The transaction is for Amvuttra sales starting on Oct. 1, with the royalty duration extending through March 2035, Royalty Pharma ( RPRX ) said.

The deal excludes fixed payments paid to Blackstone as part of the original transaction, when Blackstone invested $70 million.

Price: 37.95, Change: +0.65, Percent Change: +1.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved